Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis Delta

In brief

The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD.

Key facts

Study ID
NCT07096193
Run by
Gilead Sciences
People needed
200
Starts
2025-07-31
Expected to finish
2030-01-01
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.